Billions Spent, Few Saved: Rethinking National Institutes of Health HEAL Initiative in Light of Dopaminergic...

Despite >$3.2 billion invested across >1,800 projects by NIH's HEAL Initiative, scalable solutions for chronic pain and opioid use disorder remain limited. Continued reliance on opioid-replacement therapies often suppresses reward circuitry without restoring its neurobiology.

To articulate a neurobiologically grounded, whole-person strategy that reframes perioperative pain management as dopaminergic restoration, and to propose pragmatic clinical and policy steps for translation.

We synthesize evidence that chronic pain and addiction share hypodopaminergic mechanisms (Reward Deficiency Syndrome). We highlight precision nutraceuticals (amino-acid precursors + enkephalinase inhibitors) aimed at restoring dopamine homeostasis-especially in genetically vulnerable patients identified by the Genetic Addiction Risk Severity (GARS) test-and position them within ERAS 2.0 as adjuncts to peripheral analgesia. KEY POINTS/RECOMMENDATIONS: (1) Initiate dopaminergic repletion ~2 weeks preoperative to 4 weeks postoperative, layered with local anesthetic strategies. (2) Incorporate GARS-guided risk stratification and track MMEs, pain, function, mood/craving, LOS, and 90-day opioid persistence. (3) Prioritize multicenter pragmatic RCTs and registries with mechanistic endpoints. (4) Improve funding transparency and link HEAL-like investments to clinical outcomes dashboards.

We challenge the clinical status quo and call on spine surgeons and pain specialists to integrate dopaminergic repletion protocols within a precision-prehabilitation framework that offers a low-risk, non-opioid pathway to reduce suffering, enhance recovery, and decrease opioid dependence in spine surgery.

5 (Expert Opinion). The model integrates neurobiology, early translational signals, and policy levers to guide hypothesis-generating implementation.